Abstract
Heparin-induced thrombocytopenia (HIT) is a devastating complication of either unfractionated heparin or any of the low molecular weight heparin (LMWH) preparations. This immune-mediated process generally develops within 5–14 days of administration, although it may occur more rapidly if there has been a recent exposure, or even days to weeks after either preparation has been discontinued. Although once considered necessary for the diagnosis of HIT, thrombocytopenia is no longer essential. A 50 reduction in the platelet count from pre-heparin treatment levels is now considered a more specific finding. Immediate cessation of heparin or LMWH is recommended once the diagnosis is suspected and alternative therapy with a non-heparin anticoagulant advised due to the potential for new thrombosis, amputation or even death.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amin, D. M., Mant, T. G., Walker, S. M., Kerry, R., Lloyd, P., Lefevre, G., and Close, P. 1997. Effect of a 15-minute infusion of DDAVP on the pharmacokinetics and pharmacodynamics of REVASC during a four-hour intravenous infusion in healthy male volunteers. J. Thromb. Haemost. 77:127–132.
Amiral, J., Wolf, M., Fischer, A., Boyer-Neumann, C., Vissac, A., and Meyer, D. 1996. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br. J. Haematol. 92:954–959.
Amiral, J., Pouplard, C., Vissac, A. M., Walenga, J. M., Jeske, W., and Gruel, Y. 2000. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br. J. Haematol. 109:336–341.
Ancalmo, N., and Ochsner, J. 1990. Heparin, the miracle drug: a brief history of its discovery. J. La. State Med. Soc. 142:22–24.
Antonijevic, N. M., Savic, N. B., Perunicic, J., Kovac, M., Mikovic, D., Stanojevic, M., Calija, B., Milosevic, R. A., Obradovic, S. D., and Vasiljevic, Z. 2006. Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudin. J. Clin. Apher. 21:252–255.
Arpino, P. A., Demirjian, Z., and Van Cott, E. M. 2005. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 25:157–164.
Barrit, D. W., and Jordan, S. C. 1960. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1:1309–1312.
Bartholomew, J. R., Begelman, S. M., and Almahameed, A. 2005a. Heparin-induced thrombocytopenia: principles for early recognition and management. Cleve. Clin. J. Med. 72 (Suppl 1):S31–36.
Bartholomew, J. R., and Hursting, M. J. 2005b. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J. Thromb. Thrombolysis 19:183–188.
Bauer, K. A., Eriksson, B. I., Lassen, M. R., and Turpie, A. G. 2001. Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 345:1305–1310.
Beiderlinden, M., Treschan, T. A., Gorlinger, K., and Peters, J. 2007. Argatroban anticoagulation in critically ill patients. Ann. Pharmacother. 41:749–754.
Berilgen, J. E., Nguyen, P. H., Baker, K. R., and Rice, L. 2003. Bivalirudin treatment of heparin-induced thrombocytopenia [abstr]. Blood 102:537a.
Berkowitz, S.D. 1999. Antigenic potential of bivalirudin [abstr]. Blood 94 (suppl 1):102.
Berry, C. N., Girardot, C., Lecoffre, C., and Lunven, C. 1994. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb. Haemost. 72:381–386.
Bjork, I., Olson, S. T., and Shore, J. D. 1989. Molecular mechanisms of the accelerating effect of heparin on the reactions. between antithrombin and clottingproteinases. In Lane, D. A., and Lindhal, U. (eds.), Heparin. Clinical and biological properties clinical application, Boca Raton, Fla, CRC Press.
Bufton, M. G., et al. 2002. Bivalirudin effect on the INR and experience with prolonged inpatient and outpatient anticoagulation with bivalirudin for treatment of leg ischemia and arterial thrombosis due to HIT-TS (abstr). Blood 100:124b.
Buller, H. R., Davidson, B. L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M. H., Raskob, G., Segers, A. E. M., Cariou, R., Leeuwenkamp, O., and Lensing, A. W. A. 2004. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med. 140:867–873.
Buller, H. R., Davidson, B. L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M. H., Raskob, G., van den Berg-Segers, A. E. M., Cariou, R., Leeuwenkamp, O., and Lensing, A. W. A. 2003. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. 349:1695–1702.
Campbell, K. R., Mahaffey, K. W., Lewis, B. E., Weitz, J. I., Berkowitz, S. D., Ohman, E. M., and Califf, M. 2000. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J. Invasive Cardiol. 12 (Suppl F):14F–19F.
Cardenas, G. A., and Deitcher, S. R. 2005. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. Mayo Clin. Proc. 80:491–493.
Chong, B. H., Fawaz, I., Chesterman, C. N., and Berndt, M. C. 1989. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br. J. Haematol. 73:235–240.
Chong, B. H. 2003. Heparin-induced thrombocytopenia. J. Thromb. Haemost. 1:1471–1478.
Chong, B. H., Gallus, A. S., Cade, J. F., Magnani, H., Manoharan, A., Oldmeadow, M., Arthur, C., Richard, K., Gallo, J, Lloyd, J., Seshadri, P., and Chesterman, N. 2001 Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. J. Thromb. Haemost. 86:1170–1175.
Cimo, P. L., Moake, J. L., Weinger, R. S., Ben-Menachem, Y. B., and Khalil, K. G. 1979. Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am. J. Hematol. 6:125–133.
Cosmi, B., Fredenburgh, J. C., Rischke, J., Hirsh, J., Young, E., and Weitz, J. I. 1997. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation 95:118–124.
Cruickshank, M. K., Levine, M. N., Hirsh, J., Roberts, R., and Siguenza, M. 1991. A standard heparin nomogram for the management of heparin therapy. Arch. Intern. Med. 151:333–337.
Danielsson, A., and Bjork, I. 1981. Binding to antithrombin of heparin fractions with different molecular weights. Biochem. J. 193:427–433.
Dyke, C. M., Koster, A., Veale, J. J., Maier, G. W., McNiff, T., and Levy, J. H. 2005. Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann. Thorac. Surg. 80:299–303.
Dyke, C. M., Smedira, N. G., Koster, A., Aronson, S., McCarthy, H. L., Kirshner, R., Lincoff, A. M., and Spiess, B. D. 2006. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study. J. Thorac. Cardiovasc. Surg. 131:533–539.
Efird, L. E., and Kockler, D. R. 2006. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann. Pharmacother. 40:1383–1387.
Eichler, P., Raschke, R., Lubenow, N., Meyer, O., Schwind, P., and Greinacher, A. 2002. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br. J. Haematol. 116:887–891.
Eichler, P., Lubenow, N., Strobel, U., and Greinacher, A. 2004. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 103:613–616.
Eichler, P., Friesen, H. J., Lubenow, N., Jaeger, B., and Greinacher, A. 2000. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood 96:2373–2378.
Fabris, F., Luzzatto, G., Soini, B., Ramon, R., Scandellari, R., Randi, M. L., and Girolami, A. 2002. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J. Intern. Med. 252:149–154.
Fareed, J., Walenga, J. M., Hoppensteadt, D., Huan, X., and Racanelli, A. 1988. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 18 (Suppl 3):3–15.
Farner, B., Eichler, P., Kroll, H., and Greinacher, A. 2001. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. J. Thromb. Haemost. 85:950–957.
Fausett, M. B., Vogtlander, M., Lee, R. M., Esplin, M. S., Branch, D. W., Rodgers, G. M., and Silver, R. M. 2001. Heparin-induced thrombocytopenia is rare in pregnancy. Am. J. Obstet. Gynecol. 185:148–152.
Frame, J. N., Mulvey, K. P., Phares, J. C., and Anderson, M. J. 1989. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann. Intern. Med. 111:946–947.
Ganzer, D., Gutezeit, A., and Mayer, G. 1999. Potentials risks in drug prevention of thrombosis—low-molecular-weight heparin versus standard heparin. Z. Orthop. Ihre. Grenzgeb. 137:457–461.
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., and Ray, J. G. 2004. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl 3):338S–400S.
Girolami, B., Prandoni, P., Stefani, P. M., Tanduo, C., Sabbion, P., Eichler, P., Ramon, R., Baggio, G., Fabris, F., and Girolami, A. 2003. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101:2955–2959.
Gosselin, R. C., Dager, W. E., King, J. H., Janatpour, K., Mahackian, K., Larkin, E. C., and Owings, E. T. 2004. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am. J. Clin. Pathol. 121:593–599.
Greinacher, A., Gopinadhan, M., Gunther, J. U., Omer-Adam, M. A., Strobel, U., Warkentin, T. E., Papastravou, G. Weitschies, W., and Helm, C. A. 2006. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler. Thromb. Vasc. Biol. 26:2386–2393.
Greinacher, A., Eichler, P., Lubenow, N., Kwasny, H., and Luz, M. 2000. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846–851.
Greinacher, A., Farner, B., Kroll, H., Kohlmann, T., Warkentin, T. E., and Eichler, P. 2005. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. J. Thromb. Haemost. 94:132–135.
Greinacher, A., Eichler, P., Albrecht, D., Strobel, U., Potzsch, B., and Eriksson, B. I. 2003a. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 101:2617–2619.
Greinacher, A., Lubenow, N., and Eichler, P. 2003b. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108:2062–2065.
Greinacher, A., and Warkentin, T. E. 2004. Treatment of heparin-induced thrombocytopenia: an overview. In Heparin-induced thrombocytopenia, 3rd edition. Marcel Dekker Inc, Basel, pp. 355–370.
Herbert, J.-M., Petitou, M., and Lormeau, J.-C. 1997. SR90107A/Org31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc. Drug Ref. 15:1–26.
Hirsh, J., and Levine, M. N. 1992. Low molecular weight heparin. Blood 79:1–17.
Hirsh, J., van Aken, W. G., Gallus, A. S., Dollery, C. T., Cade, J. F., and Yung, W. L. 1976. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 53:691–695.
Hirsh, J. 1991. Heparin. N. Engl. J. Med. 324:1565–1574.
Hirsh, J., and Raschke, R. 2004a. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl 3):188S–203S.
Hirsh, J., Heddle, N., and Kelton, J. G. 2004b. Treatment of heparin-induced thrombocytopenia: a critical review. Arch. Intern. Med. 164:361–369.
Ibbotson, S. H., Grant, P. J., Kerry, R., Findlay, V. S., and Prentice, C. R. 1991. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. J. Thromb. Haemost. 65:64–66.
Irani, M. S., White, H. J. Jr., Sexon, R. G. 1995. Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am. J. Cardiol. 75(5):422–423.
Irvin, W., Sica, D., Gehr, T., McAllister, A., Rogge, M., Charenkavanich, S., and Adelman, B. 1999. Pharmacodynamics (PD) and kinetics (PK) of bivalirudin (BIV) in renal failure (RF) and hemodialysis (HD) [abstr]. Clin. Pharmacol. Ther. 65:202.
Kaplan, K. L., and Francis, C. W. 2002. Direct thrombin inhibitors. Semin. Hematol. 39:187–196.
Kappers-Klunne, M. C., Boon, D. M., Hop, W. C., Michiels, J. J., Stibbe, J., van der Zwaan, C., Koudstaal, P. J., and van Vliet, H. H. D. M. 1997. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br. J. Haematol. 96:442–446.
Kearon, C., Ginsberg, J. S., Julian, J. A., Douketis, J., Solymoss, S., Ockelford, P., Jackson, S., Turpie, A. G., MacKinnon, B., Hirsh, J., and Gent, M. 2006. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296:935–942.
Kearon, C., Johnston, M., Moffat, K., McGinnis, J., and Ginsberg, J. S. 1998. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch. Intern. Med. 158:1140–1143.
Klenner, A. F., Lubenow, N., Raschke, R., and Greinacher, A. 2004. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. J. Thromb. Haemost. 91:719–724.
Koster, A., Dyke, C. M., Aldea, G., Smedira, N. G., McCarthy, H. L., Aronson, S., Hetzer, R., Avery, E., Spiess, B., and Lincoff, A. M. 2007. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann. Thorac. Surg. 83:572–577.
Levy, J. H., and Hursting, M. J. 2007. Heparin-induced thrombocytopenia, a prothrombotic disease. Hematol. Oncol. Clin. North Am. 21:65–88.
Lewis, B. E., Wallis, D. E., Berkowitz, S. D., Matthai, W. H., Fareed, J., Walenga, J. M., and Bartholomew, J. 2001. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838–1843.
Lewis, B. E., Wallis, D. E., Leya, F., Hursting, M. J., and Kelton, J. G. 2003. Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Intern. Med. 163:1849–1856.
Lindhoff-Last, E., Nakov, R., Misselwitz, F., Breddin, H. K., and Bauersachs, R. 2002. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br. J. Haematol. 118:1137–1142.
Linkins, L. A., and Weitz, J. I. 2005. Pharmacology and clinical potential of direct thrombin inhibitors. Curr. Pharm. Des. 11:3877–3884.
Lo, G. K., Juhl, D., Warkentin, T. E., Sigouin, C. S., Eichler, P., and Greinacher, A. 2006. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J. Thromb. Haemost. 4:759–765.
Lubenow, N., Kempf, R., Eichner, A., Eichler, P., Carlsson, L. E., and Greinacher, A. 2002. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122:37–42.
Lubenow, N., Eichler, P., Lietz, T., and Greinacher, A, Hit Investigators Group. 2005. Lepirudin in patients with heparin-induced thrombocytopenia – results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J. Thromb. Haemost. 3:2428–2436.
Luster, A. D. 1998. Chemokines—chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:436–445.
Magnani, H. N., and Gallus, A. 2006. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. J. Thromb. Haemost. 95:967–981.
Mahaffey, K. W., Lewis, B. E., Wildermann, N. M., Berkowitz, S. D., Oliverio, R. M., Turco, M. A., Shalev, Y., Ver Lee, P., Traverse, J. H., Rodriguez, A. R., Ohman, E. M., Harrington, R. A., and Califf, R. M. 2003. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J. Invasive Cardiol. 15:611–616.
Mahlfeld, K., Franke, J., Schaeper, O., Kayser, R., and Grasshoff, H. 2002. Heparin-induced thrombocytopenia as a complication of postoperative prevention of thromboembolism with unfractionated heparin/low molecular weight heparin after hip and knee prosthesis implantation. Unfallchirurg 105:327–331.
Makhoul, R. G., McCann, R. L., Austin, E. H., Greenberg, C. S., and Lowe, J. E. 1987. Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. Ann. Thorac. Surg. 43:617–621.
Marx, A., Huhle, G., Hoffmann, U., Wang, L. C., Schule, B., Jani, L., and Harenberg, J. 1999. Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin. Z. Orthop. Ihre. Grenzgeb. 137:536–539.
Merry, A. F., Raudkivi, P. J., Middleton, N. G., McDougall, J. M., Nand, P., Mills, B. P., Webber, B. J., Frampton, C. M., and White, H. D. 2004. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann. Thorac. Surg. 77:925–931; discussion 931.
Mon, C., Moreno, G., Ortiz, M., Diaz, R., Herrero, J. C., Oliet, A., Rodriguez, I., Ortega, O., Gallar, P., and Vigil, A. 2006. Treatment of hirudin overdosage in a dialysis patient with heparin-induced thrombocytopenia with mixed hemodialysis and hemofiltration treatment. Clin. Nephrol. 66:302–305.
Newman, P. M., Swanson, R. L., and Chong, B. H. 1998. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. J. Thromb. Haemost. 80:292–297.
Olinger, G. N., Hussey, C. V., Olive, J. A., and Malik, M. I. 1984. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J. Thorac. Cardiovasc. Surg. 87:673–677.
Opatrny, L., and Warner, M. N. 2004. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am. J. Hematol. 76:240–244.
Oppenheim, J. J., Zachariae, C. O., Mukaida, N., and Matsushima, K. 1991. Properties of the novel proinflammatory supergene “intercrine” cytokine family. Annu. Rev. Immunol. 9:617–648.
Potzsch, B., Klovekorn, W. P., and Madlener, K. 2000. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N. Engl. J. Med. 343:515.
Pouplard, C., May, M. A., Regina, S., Marchand, M., Fusciardi, J., and Gruel, Y. 2005. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br. J. Haematol. 128:837–841.
Prandoni, P., Siragusa, S., Girolami, B., and Fabris, F., BELZONI Investigators Group. 2005. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 106:3049–3054.
Ramirez, L. M., Carman, T. L., Begelman, S. M., AlMahameed, A., Joseph, D., Kashyap, V., White, D. A., Andersen-Harris, K., and Bartholomew, J. R. 2005. Bivalirudin in patients with clinically suspected HIT or history of HIT [abstr]. Blood 106:269a.
Raschke, R. A., Reilly, B. M., Guidry, J. R., Fontana, J. R., and Srinivas, S. 1993. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann. Intern. Med. 119:874–881.
Reed, M. D. and Bell, D. 2002. Clinical pharmacology of bivalirudin. Pharmacotherapy 22(6 Pt 2):105S–111S.
Rhodes, G. R., Dixon, R. H., and Silver, D. 1973. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg. Gynecol. Obstet. 136:409–416.
Rhodes, G. R., Dixon, R. H., and Silver, D. 1977. Heparin induced thrombocytopenia: eight cases with thrombotic-hemorrhagic complications. Ann. Surg. 186:752–758.
Robinson, J. A., and Lewis, B. E. 1999. Plasmapheresis in the management of heparin-induced thrombocytopenia. Semin. Hematol. 36(Suppl 1):29–32.
Robson, R. 2000. The use of bivalirudin in patients with renal impairment. J. Invasive Cardiol. 12 (Suppl F):33F–36F.
Robson, R., White, H., Aylward, P., and Frampton, C. 2002. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin. Pharmacol. Ther. 71:433–439.
Rollins, B. J. 1997. Chemokines. Blood 90:909–928.
Ross, B. P., and Toth, I. 2005 Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Current Drug Delivery. 2:277–287.
Savi, P., Chong, B. H., Greinacher, A., Gruel, Y., Kelton, J. G., Warkentin, T. E., Eichler, P., Meuleman, D., Petitou, M., Herault, J.-P., Cariou, R., and Herbert, J.-M. 2005. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 105:139–144.
Sciulli, T. M. and Mauro, V. F. 2002. Pharmacology and clinical use of bivalirudin. Ann. Pharmacother. 36:1028–1041.
Selleng, S., Lubenow, N., Wollert, H. G., Mullejans, B., and Greinacher, A. 2001. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann. Thorac. Surg. 71:1041–1042.
Sheridan, D., Carter, C., and Kelton, J. G. 1986. A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27–30.
Sheth, S. B., DiCicco, R. A., Hursting, M. J., Montague, T., and Jorkasky, D. K. 2001. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. J. Thromb. Haemost. 85:435–440.
Shuster, T. A., Silliman, W. R., Coats, R. D., Mureebe, L., and Silver, D. 2003. Heparin-induced thrombocytopenia: twenty-nine years later. J. Vasc. Surg. 38:1316–1322.
Smedira, N. G., Dyke, C. M., Koster, A., Jurmann, M., Bhatia, D. S., Hu, T., McCarthy, H. L., Lincoff, A. M., Spiess, B. D., and Aronson, S. 2006. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J. Thorac. Cardiovasc. Surg. 131:686–692.
Smythe, M. A., Stephens, J. L., Koerber, J. M., and Mattson, J. C. 2005. A comparison of lepirudin and argatroban outcomes. Clin. Appl. Thromb. Hemost. 11:371–374.
Spinler, S. A. 2006. New concepts in heparin-induced thrombocytopenia: diagnosis and management. J. Thromb. Thrombolysis 21:17–21.
Srinivasan, A. F., Rice, L., Bartholomew, J. R., Rangaswamy, C., La Perna, L., Thompson, J. E., Murphy, S., and Baker, K. R. 2004. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch. Intern. Med. 164:66–70.
Trask, A. S., Gosselin, R. C., Diaz, J. A., and Dager, W. E. 2004. Warfarin initiation and monitoring with clotting factors II, VII, and X. Ann. Pharmacother. 38:251–256.
Turpie, A. G., Bauer, K. A., Eriksson, B. I., and Lassen, M. R., PENTATHALON 2000 Study Steering Committee. 2002. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359:1721–1726.
Walenga, J. M., Jeske, W. P., Prechel, M. M., Bacher, P., and Bakhos, M. 2004. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin. Thromb. Hemost. 30 (Suppl 1):69–80.
Wallis, D. E., Workman, D. L., Lewis, B. E., Steen, L., Pifarre, R., and Moran, J. F. 1999 Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am. J. Med. 106:629–635.
Warkentin, T. E., Hayward, C. P., Boshkov, L. K., Santos, A. V., Sheppard, J. A., Bode, A. P., and Kelton J. G. 1994. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691–3699.
Warkentin, T. E. and Kelton, J. G. 2001. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344:1286–1292.
Warkentin, T. E. and Greinacher, A. 2004. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl 3):311S–337S.
Warkentin, T. E., Sheppard, J. A., Horsewood, P., Simpson, P. J., Moore, J. C., and Kelton, J. G. 2000. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703–1708.
Warkentin, T. E., Levine, M. N., Hirsh, J., Horsewood, P., Roberts, R. S., Gent, M., and Kelton, J. G. 1995. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332:1330–1335.
Warkentin, T. E. and Kelton, J. G. 1996. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101:502–507.
Warkentin, T. E. 1999. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. J. Thromb. Haemost. 82:439–447.
Warkentin, T. E. 2003a. Heparin-induced thrombocytopenia: pathogenesis and management. Br. J. Haematol. 121:535–555.
Warkentin, T. E. and Heddle, N. M. 2003b. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr. Hematol. Rep. 2:148–157.
Warkentin, T. E. 2005a. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 127(Suppl 2):35S–45S.
Warkentin, T. E., Cook, R. J., Marder, V. J., Sheppard, J. A., Moore, J. C., Eriksson, B. I., Greinacher, A., and Kelton, J. G. 2005b. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106:3791–3796.
Warkentin, T. E., Greinacher, A., Craven, S., Dewar, L., Sheppard, J. A., and Ofosu, F. A. 2005c. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. J. Thromb. Haemost. 94:958–964.
Warkentin, T. E., Maurer, B. T., and Aster, R. H. 2007. Heparin-induced thrombocytopenia associated with fondaparinux. N. Engl. J. Med. 356:2653–2655.
Weisman, R. E. and Tobin, R. W. 1958. Arterial embolism occurring during systemic heparin therapy. Arch. Surg. 76:219–225; discussion 225–227.
Winder, A., Shoenfeld, Y., Hochman, R., Keren, G., Levy, Y., and Eldor, A. 1998. High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response. J. Clin. Immunol. 18:330–334.
Yeh, R. W. and Jang, I. K. 2006. Argatroban: update. Am. Heart J. 151:1131–1138.
Young, E., Cosmi, B., Weitz, J., and Hirsh, J. 1993. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. J. Thromb. Haemost. 70:625–630.
Yusuf, S., Mehta, S. R., Chrolavicius, S., Afzal, R., Pogue, J., Granger, C. B., Budaj, A, Peters, R. J., Bassand, J. P., Wallentin, L., Joyner, C., and Fox, K. A. 2006a. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530.
Yusuf, S., Mehta, S. R., Chrolavicius, S., Afzal, R., Pogue, J., Granger, C. B., Budaj, A, Peters, R. J., Bassand, J. P., Wallentin, L., Joyner, C., and Fox, K. A. 2006b. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354:1464–1476.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Celestin, C.A., Bartholomew, J.R. (2008). Heparin-Induced Thrombocytopenia. In: Weert, M.v., Møller, E.H. (eds) Immunogenicity of Biopharmaceuticals. Biotechnology: Pharmaceutical Aspects, vol VIII. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75841-1_12
Download citation
DOI: https://doi.org/10.1007/978-0-387-75841-1_12
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-75840-4
Online ISBN: 978-0-387-75841-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)